NCT00695630View on ClinicalTrials.gov

Flumazenil Reversal of Oral Triazolam

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Dental Anxiety
Interventions
DRUG

Flumazenil

2 mL, 0.2 mg SM

DRUG

Placebo

2 mL sterile saline SM

Trial Locations (1)

98195

Dental Fears Research Clinic, Seattle

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Washington

OTHER

NCT00695630 - Flumazenil Reversal of Oral Triazolam | Biotech Hunter | Biotech Hunter